Patients in a first-of-its-kind clinical trial will receive a vastly expanded dose of their own T cells — white blood cells that are the specialized warriors of the immune system — followed by a cancer immunotherapy drug known to promote the activation and survival of T cells.
“We’re excited about this combination because there’s no standard of care now for our metastatic melanoma patients if immune checkpoint blockade drugs fail...
The 90 percent of cancer patients who experience pain due to nerve damage caused by tumors, surgery, chemotherapy or radiation may someday...
Receptors for leptin, a protein hormone, may be associated with tumor recurrence in patients with renal cell carcinoma (RCC), providing further...
Eight of MD Anderson Cancer Center's top young researchers have been named Andrew Sabin Family Fellows and will receive $100,000 over two years to pursue creative, independent thinking and high-risk, high-impact research.
In late 2015, Andrew Sabin, of East Hampton, N.Y., and the Andrew Sabin Family Foundation committed $30 million to establish an endowment funding the Andrew Sabin Family Fellowship Program, which is designed...
Researchers at MD Anderson Cancer Center have announced a new method for detecting DNA mutations in a single cancer cell versus current technology...
The Affordable Care Act (ACA) was signed into law in 2010 to improve access to affordable health coverage for Americans, and a major focus...
The drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a new MD...
MD Anderson Cancer Center fully supports new rules recently issued by the Food and Drug Administration (FDA) to extend federal regulatory...
Long associated with liver cancer and non-Hodgkin’s lymphoma, the hepatitis C virus (HCV) for the first time has been associated with certain...
Researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab on...